• Explore /
  • Poster
  • / Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

Abstract Video & Slides Poster

Authors

null

Henry Jacob Conter

University of Western Ontario, Brampton, ON, Canada

Henry Jacob Conter , Neal D. Shore , William R. Berry , Peter C.C. Fong , Jose Maria M. Piulats Rodriguez , Leonard Joseph Appleman , Tilman Todenhöfer , Gwenaelle Gravis , Brigitte Laguerre , Howard Gurney , Margitta Retz , Emanuela Romano , Loic Mourey , Johann S. De Bono , Audrey E. Kam , Urban Emmenegger , Haiyan Wu , Ping Qiu , Charles Schloss , Evan Y. Yu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT02861573

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5545)

DOI

10.1200/JCO.2020.38.15_suppl.5545

Abstract #

5545

Poster Bd #

126

Abstract Disclosures

Similar Posters

First Author: Srikala S. Sridhar

First Author: Evan Y. Yu

First Author: Peter C.C. Fong

First Author: Emmanuel S. Antonarakis